Handa Pharmaceuticals, Inc. (TPEX:6620)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
72.00
+0.30 (0.42%)
May 29, 2026, 1:30 PM CST
Market Cap11.92B +2.6%
Revenue (ttm)1.76B +121.4%
Net Income780.80M +94.8%
EPS4.85 +72.0%
Shares Out 165.53M
PE Ratio14.86
Forward PEn/a
Dividend2.00 (2.78%)
Ex-Dividend Daten/a
Volume270,694
Open71.80
Previous Close71.70
Day's Range71.00 - 72.00
52-Week Range67.30 - 154.00
Beta0.80
Analystsn/a
Price Targetn/a
Earnings DateAug 13, 2026

About Handa Pharmaceuticals

Handa Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development of drugs for various diseases in the United States. The company offers ONCORE, a proprietary drug delivery technology that was developed to improve the patient compliance and safety of the tyrosine kinase inhibitor of oncology drugs; Tascenso ODT for the treatment of multiple sclerosis; and HND-033, HND-039, and HND-027 for oncology diseases. It also provides Quetiapine XR to treat Schizophrenia; Dexlansoprazole DR capsules to treat erosive esophagitis a... [Read more]

Sector Healthcare
Founded 2014
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6620
Full Company Profile

Financial Performance

In 2025, Handa Pharmaceuticals's revenue was 1.73 billion, an increase of 108.17% compared to the previous year's 830.67 million. Earnings were 749.77 million, an increase of 58.60%.

Financial Statements